China OKs its first mRNA vaccine, from drugmaker CSPC | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Monday
June 05, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
MONDAY, JUNE 05, 2023
China OKs its first mRNA vaccine, from drugmaker CSPC

Coronavirus chronicle

Reuters
23 March, 2023, 09:50 am
Last modified: 23 March, 2023, 09:54 am

Related News

  • US defense secretary discusses upgrading ties with India to counter China
  • United Nations 'alarmed' by Hong Kong June 4 detentions
  • Chinese warship passed in 'unsafe manner' near US destroyer in Taiwan Strait, military officials say
  • 19 killed in southwest China landslide covering mine worker dormitory
  • China tightens access to Tiananmen Square, 32 detained in Hong Kong on anniversary of 1989 protests

China OKs its first mRNA vaccine, from drugmaker CSPC

Reuters
23 March, 2023, 09:50 am
Last modified: 23 March, 2023, 09:54 am
An employee works on the production line of CanSino Biologics Inc's single-dose vaccine against the coronavirus disease (Covid-19) in Tianjin, China April 25, 2021. Picture taken April 25, 2021. China Daily via REUTERS
An employee works on the production line of CanSino Biologics Inc's single-dose vaccine against the coronavirus disease (Covid-19) in Tianjin, China April 25, 2021. Picture taken April 25, 2021. China Daily via REUTERS

China has approved its first domestically developed mRNA vaccine against Covid-19, CSPC Pharmaceutical Group Ltd 1093.HK said on Wednesday, a major achievement in a country that has declined to use Western Covid shots to support domestic research.

China, whose home-grown vaccines are seen as less effective than the Moderna MRNA.O and Pfizer PFE.N-BioNTech 22UAy.DE mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.

The long-awaited approval comes as infections have fallen sharply across China since it suddenly dropped its strict "zero-Covid" curbs in December, making the sales outlook for the newly approved vaccine moderate.

But it would give China an additional option to tackle future outbreaks and a base for development against newly emerging variants, scientists said.

The news of China's first successful mRNA vaccine did not generate much buzz in domestic social media on Wednesday, as the country has returned to normal and its borders have re-opened.

Its top leaders declared a "decisive victory" over Covid last month.

CSPC said its vaccine trials showed adverse effects were substantially lower in an elderly group compared with an adult group, which could be help China, which has stressed the need to focus on protecting its vulnerable elderly population.

The company said its independently developed mRNA vaccine SYS6006 targets some major Omicron variants and its booster dose showed good neutralization effect against Omicron subvariants BA.5, BF.7, BQ.1.1., XBB.1.5 and CH.1.1. in clinical trials.

In a study of 4,000 participants from Dec. 10 to Jan. 18 when China was experiencing a surge in infections, the vaccine showed efficacy of 85.3% 14 to 28 days after a booster vaccination.

CSPC did not say how many doses it plans to produce. It said the vaccine could be stored at 2 degrees to 8 degrees C (35.6 degrees to 46.4 degrees F) for a long time.

"The group has built a good manufacturing practice-compliant production plant (for the vaccine)," it said in a statement.

"Key raw materials and excipients are produced by the group, which enables independent control in the supply chain and significantly lower production cost."

The firm won emergency approval for clinical trials of the mRNA shot in April last year, around the same time as CanSino, another China-based company that is testing an mRNA Omicron booster shot.

CSPC reported a rise of 8.7% in 2022 net profit on Wednesday, helped by several newly launched generic drugs included in the national drug procurement programme.

Its shares rose as much as 7.7% after the result and news of the approval.

"mRNA vaccines are an important new technology and will play a major role in future to prevent infections," said David Heymann, an infectious disease specialist.

World Health Organization officials have in the past described mRNA vaccines as a "very solid option" for countries including China, particularly for vulnerable populations and for use as boosters.

Heymann said it was now important for CSPC to share its data on the vaccine with the WHO so the UN agency can also assess the shot for use in international markets.

Top News / World+Biz / China

China / mRNA / Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • FILE PHOTO: A passenger plane is seen with the moon behind as it flies over London, Britain, January 4, 2020. REUTERS/Toby Melville
    Bangladesh withholds $214m in airline funds; 2nd among top 5 countries: IATA
  • An anatomy of power crisis
    An anatomy of power crisis
  • How BSRM turns steel waste into eco-friendly construction material
    How BSRM turns steel waste into eco-friendly construction material

MOST VIEWED

  • Covid is no longer global health emergency: WHO
    Covid is no longer global health emergency: WHO
  • Federal police officers stand guard near the house of former Brazilian President Jair Bolsonaro, during a search operation at his home, in Brasilia, Brazil, 3 May, 2023. REUTERS/Adriano Machado
    Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • World Health Organization logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration//File Photo
    Covid here to stay but moving out of emergency phase: WHO
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India reports 12,591 new Covid cases today, 20% more than yesterday
  • People queue up outside a quick test centre to take their coronavirus disease (Covid-19) antigen rapid tests, in Singapore September 21, 2021. Photo :Reuters
    Singapore witnesses new Covid wave: ‘Cases are mostly mild’
  • India's active case count now stands at 3.90 per cent. ( HT file Photo)
    India logs 5,676 new Covid cases, active infections cross 37,000-mark

Related News

  • US defense secretary discusses upgrading ties with India to counter China
  • United Nations 'alarmed' by Hong Kong June 4 detentions
  • Chinese warship passed in 'unsafe manner' near US destroyer in Taiwan Strait, military officials say
  • 19 killed in southwest China landslide covering mine worker dormitory
  • China tightens access to Tiananmen Square, 32 detained in Hong Kong on anniversary of 1989 protests

Features

Beating plastic pollution: Local startups build businesses around waste

Beating plastic pollution: Local startups build businesses around waste

5h | Panorama
New battleground of global powers

New battleground of global powers

20h | Panorama
Understanding the Indo-Pacific: A case of two rivalries

Understanding the Indo-Pacific: A case of two rivalries

20h | Panorama
US and its allies in the Ind-Pacific

US and its allies in the Ind-Pacific

20h | Panorama

More Videos from TBS

Young Entrepreneurs Beating Plastic Pollution

Young Entrepreneurs Beating Plastic Pollution

3h | TBS Stories
The fitness industry of Bangladesh tries to reshape from corona effect

The fitness industry of Bangladesh tries to reshape from corona effect

18h | TBS Stories
Ukraine ready to launch counteroffensive

Ukraine ready to launch counteroffensive

21h | TBS World
Mughal Emperor Shah Jahan's food on the streets of Dhaka

Mughal Emperor Shah Jahan's food on the streets of Dhaka

1d | TBS Food

Most Read

1
bKash denied permission to pay $4.10 lakh for Argentina football partnership
Banking

bKash denied permission to pay $4.10 lakh for Argentina football partnership

2
Boeing offers Biman its latest 787-10 Dreamliner
Bangladesh

Boeing offers Biman its latest 787-10 Dreamliner

3
Photo: Noor-A-Alam/TBS
Splash

The Night Dhaka did NOT vibe with Anuv Jain

4
Country's first floating solar power plant connected to national grid
Energy

Country's first floating solar power plant connected to national grid

5
Photo: TBS
Environment

Green space in Dhaka North declines 66% in 3 decades: Study

6
File Photo: Mohammad Minhaj Uddin/TBS
Bangladesh

Low-cost housing planned for 4 lakh Bangabandhu Shilpa Nagar workers

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net